Browse our 650+ Publications​

Latest Publications

Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA.

Cavo M, et al.
Blood
February 2022
Authors and Affiliates
Michele Cavo,1 Jesus San-Miguel,2 Saad Z. Usmani,3 Katja Weisel,4 Meletios A. Dimopoulos,5 Herve Avet-Loiseau,  6 Bruno Paiva,2 Nizar J. Bahlis,7 Torben Plesner,8 Vania Hungria,9 Philippe Moreau,10 Maria-Victoria Mateos,11 Aurore Perrot,12 Shinsuke Iida,13 Thierry Facon,14 Shaji Kumar,15 Niels W. C. J. van de Donk,16 Pieter Sonneveld,17 Andrew Spencer,18 Maria Krevvata,19 Christoph Heuck,19 Jianping Wang,20 Jon Ukropec,21 Rachel Kobos,19 Steven Sun,20 Mia Qi,20 and Nikhil Munshi22,23 1IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seragnoli ”, Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Universita di Bologna, Bologna, Italy;  2 Clınica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), IDISNA, CIBER-ONC, Pamplona, Spain; 3Levine Cancer Institute/Atrium Health, Charlotte, NC; 4Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; 5National and Kapodistrian University of Athens, Athens, Greece; 6Unite de Genomique du Myelome, IUC-Oncopole, Toulouse, France; 7Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, AB, Canada; 8Vejle Hospital and University of Southern Denmark, Vejle, Denmark; 9 Clinica Medica Sao Germano, S ao Paulo, Brazil; 10Hematology, University Hospital Hotel-Dieu, CHU Nantes, Nantes, France; 11University Hospital of Salamanca/IBSAL/Cancer Research Center-IBMCC (USAL-CSIC), Salamanca, Spain; 12Hematology Department, University Cancer Institute IUCT, Toulouse, France; 13Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Mizuho-ku Nagoya, Japan; 14University of Lille, CHU Lille, Service des Maladies du Sang, Lille, France; 15Department of Hematology, Mayo Clinic Rochester, Rochester, MN; 16Department of Hematology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands; 17Erasmus MC, Rotterdam, The Netherlands; 18Malignant Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University, Melbourne, Australia; 19Janssen Research & Development, LLC, Spring House, PA; 20Janssen Research & Development, LLC, Raritan, NJ; 21Janssen Global Medical Affairs, Horsham, PA; 22Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and 23Veterans Administration Boston Healthcare System, West Roxbury, MA

Decade-long leukaemia remissions with persistence of CD4 + CAR T cells

Melenhorst JJ, et al.
February 2022
Authors and Affiliates
J Joseph Melenhorst #,1,2,3,4,5, Gregory M Chen #,6, Meng Wang #,7,8,9, David L Porter #,9,10, Changya Chen 11,12, McKensie A Collins 7,8,9,13, Peng Gao 11,12, Shovik Bandyopadhyay 13, Hongxing Sun 7,8,9, Ziran Zhao 7,8,9, Stefan Lundh 7,8,9, Iulian Pruteanu-Malinici 14, Christopher L Nobles 15, Sayantan Maji 7,8,9, Noelle V Frey 9, Saar I Gill 9, Lifeng Tian 7,9, Irina Kulikovskaya 7,8,9, Minnal Gupta 7,8,9, David E Ambrose 7,8,9, Megan M Davis 7,8,9, Joseph A Fraietta 7,8,9,15, Jennifer L Brogdon 14, Regina M Young 7,8,9, Anne Chew 7,8,9, Bruce L Levine 7,8,9, Donald L Siegel 7,8,16, Cécile Alanio 17,18,19, E John Wherry 17,18,19, Frederic D Bushman 15, Simon F Lacey 7,8,9, Kai Tan 20,21,22,23,24, Carl H June 25,26,27,28,29; 1 Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. mej@pennmedicine.upenn.edu. 2 Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. mej@pennmedicine.upenn.edu. 3 Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. mej@pennmedicine.upenn.edu. 4 Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. mej@pennmedicine.upenn.edu. 5 Parker Institute for Cancer Immunotherapy, University of Pennsylvania, Philadelphia, USA. mej@pennmedicine.upenn.edu. 6 Graduate Group in Genomics and Computational Biology, University of Pennsylvania, Philadelphia, PA, USA. 7 Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 8 Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 9 Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 10 Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 11 Center for Childhood Cancer Research, The Children's Hospital of Philadelphia, Philadelphia, PA, USA. 12 Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA. 13 Graduate Group in Cell & Molecular Biology, University of Pennsylvania, Philadelphia, PA, USA. 14 Novartis Institute for Biomedical Research, Cambridge, MA, USA. 15 Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 16 Department of Transfusion Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 17 Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 18 Parker Institute for Cancer Immunotherapy, University of Pennsylvania, Philadelphia, USA. 19 Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 20 Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. tank1@chop.edu. 21 Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. tank1@chop.edu. 22 Graduate Group in Genomics and Computational Biology, University of Pennsylvania, Philadelphia, PA, USA. tank1@chop.edu. 23 Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA. tank1@chop.edu. 24 Graduate Group in Cell & Molecular Biology, University of Pennsylvania, Philadelphia, PA, USA. tank1@chop.edu. 25 Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. cjune@upenn.edu. 26 Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. cjune@upenn.edu. 27 Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. cjune@upenn.edu. 28 Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. cjune@upenn.edu. 29 Parker Institute for Cancer Immunotherapy, University of Pennsylvania, Philadelphia, USA. cjune@upenn.edu. # Contributed equally.

Changes in T-cell subsets and clonal repertoire during chemoimmunotherapy with pembrolizumab and paclitaxel or capecitabine for metastatic triple-negative breast cancer

Chun B, et al.
Journal for ImmunoTherapy of Cancer
February 2022
Authors and Affiliates
Brie Chun 1, Joanna Pucilowska 2, ShuChing Chang 3, Isaac Kim 1, Benjamin Nikitin 1, Yoshinobu Koguchi 1, William L Redmond 1, Brady Bernard 1 4, Venkatesh Rajamanickam 1,4, Nathan Polaske 5, Paul A Fields 5, Valerie Conrad 1, Mark Schmidt 1, Walter J Urba 1, Alison K Conlin 1, Heather L McArthur 6, David B Page 7; 1 Earle A Chiles Research Institute, Providence Cancer Institute, Portland, Oregon, USA. 2 Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, USA. 3 Medical Data Research Center, Providence St Joseph Health, Portland, Oregon, USA. 4 Computational Immuno-Oncology and Bioinformatics Core, Earle A. Chiles Research Institute, Portland, Oregon, USA. 5 Adaptive Biotechnologies Corp, Seattle, Washington, USA. 6 Department of Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA. 7 Earle A Chiles Research Institute, Providence Cancer Institute, Portland, Oregon, USA david.page2@providence.org.

Multi-objective optimization reveals time- and dose-dependent inflammatory cytokine-mediated regulation of human stem cell derived T-cell development

Edgar JM, et al.
npj Regenerative Medicine
February 2022
Authors and Affiliates
John M Edgar 1, Yale S Michaels 1, Peter W Zandstra 2,3; 1 School of Biomedical Engineering, University of British Columbia, Vancouver, BC, V6T 1Z3, Canada. 2 School of Biomedical Engineering, University of British Columbia, Vancouver, BC, V6T 1Z3, Canada. peter.zandstra@ubc.ca. 3 Michael Smith Laboratories, University of British Columbia, Vancouver, BC, V6T 1Z4, Canada. peter.zandstra@ubc.ca.

Identification of shared tumor epitopes from endogenous retroviruses inducing high-avidity cytotoxic T cells for cancer immunotherapy

Bonaventura P, et al.
Science Advances
February 2022
Authors and Affiliates
Paola Bonaventura 1,2, Vincent Alcazer 1, Virginie Mutez 3, Laurie Tonon 4, Juliette Martin 5, Nicolas Chuvin 3, Emilie Michel 3, Rasha E Boulos 3, Yann Estornes 3, Jenny Valladeau-Guilemond 1, Alain Viari 4, Qing Wang 6, Christophe Caux 1,2, Stéphane Depil 1,2,3,7; 1 Centre de Recherche en Cancérologie de Lyon (CRCL), UMR INSERM U1052 CNRS 5286, Lyon, France. 2 Centre Léon Bérard, Lyon, France. 3 ErVaccine Technologies, Lyon, France. 4 Synergie Lyon Cancer, Plateforme de bioinformatique « Gilles Thomas », Lyon, France. 5 CNRS-Institut de Biologie et Chimie des Protéines UMR 5086, Lyon, France. 6 Complete Omics, Baltimore, MD, USA. 7 Université Claude Bernard Lyon 1, Lyon, France.

Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE.

San-Miguel J, et al.
Blood
January 2022
Authors and Affiliates
Jesus San-Miguel,1 Herve Avet-Loiseau, 2 Bruno Paiva,1 Shaji Kumar,3 Meletios A. Dimopoulos,4 Thierry Facon,5 Marıa-Victoria Mateos, 6Cyrille Touzeau,7 Andrzej Jakubowiak,8 Saad Z. Usmani,9 Gordon Cook,10 Michele Cavo,11 Hang Quach,12 Jon Ukropec,13 Priya Ramaswami,14 Huiling Pei,14 Mia Qi,15 Steven Sun,15 Jianping Wang,15 Maria Krevvata,16 Nikki DeAngelis,16 Christoph Heuck,16 Rian Van Rampelbergh,17 Anupa Kudva,15 Rachel Kobos,15 Ming Qi,16 and Nizar J. Bahlis,18 1Clınica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC number CB16/12/00369, Pamplona, Spain; 2Unite de Genomique du Myelome, IUC-Oncopole, Toulouse, France; 3Department of Hematology, Mayo Clinic, Rochester,MN; 4National and Kapodistrian University of Athens, Athens, Greece; 5University of Lille, CHU Lille, Service des Maladies du Sang, Lille, France; 6University Hospital of Salamanca/IBSAL/Cancer Research Center-IBMCC (USAL-CSIC), Salamanca, Spain; 7Hematology, University Hospital Hotel-Dieu, Nantes, France; 8University of Chicago Medical Center, Chicago, IL; 9Levine Cancer Institute/Atrium Health, Charlotte, NC; 10Leeds Cancer Centre, Leeds Teaching Hospitals NHS Trust and University of Leeds, Leeds, United Kingdom; 11IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seragnoli, ” Universita di Bologna, Bologna, Italy; 12University of Melbourne, St. Vincent’s Hospital, Melbourne, VIC; 13Janssen Global Medical Affairs, Horsham, PA; 14Janssen Research & Development, LLC, Titusville, NJ; 15Janssen Research & Development, LLC, Raritan, NJ; 16Janssen Research & Development, LLC, Spring House, PA; 17Janssen Research & Development, Beerse, Belgium; and 18Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, AB, Canada

T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma

Lozano AX, et al.
Nature Medicine
January 2022
Authors and Affiliates
Alexander X Lozano #,1,2, Aadel A Chaudhuri #,3,4,5,6, Aishwarya Nene #,7, Antonietta Bacchiocchi 8, Noah Earland 9, Matthew D Vesely 8, Abul Usmani 9, Brandon E Turner 10, Chloé B Steen 10,11, Bogdan A Luca 12, Ti Badri 13, Gunsagar S Gulati 10, Milad R Vahid 10, Farnaz Khameneh 10, Peter K Harris 9, David Y Chen 14,15, Kavita Dhodapkar 16, Mario Sznol 17,18, Ruth Halaban 8,18, Aaron M Newman #,19,20; 1 Department of Materials Science and Engineering, Stanford University, Stanford, CA, USA. 2 Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada. 3 Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO, USA. aadel@wustl.edu. 4 Department of Genetics, Washington University School of Medicine, St. Louis, MO, USA. aadel@wustl.edu. 5 Department of Computer Science & Engineering, Washington University, St. Louis, MO, USA. aadel@wustl.edu. 6 Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, USA. aadel@wustl.edu. 7 Yale School of Medicine, Yale University, New Haven, CT, USA. 8 Department of Dermatology, Yale University School of Medicine, New Haven, CT, USA. 9 Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO, USA. 10 Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, CA, USA. 11 Department of Biomedical Data Science, Stanford University, Stanford, CA, USA. 12 Stanford Center for Biomedical Informatics Research, Stanford University, Stanford, CA, USA. 13 Department of Immunobiology, Yale University School of Medicine, New Haven, CT, USA. 14 Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, USA. 15 Division of Dermatology, Washington University School of Medicine, St. Louis, MO, USA. 16 Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Emory University, Atlanta, GA, USA. 17 Department of Medicine, Division of Medical Oncology, Yale University School of Medicine, New Haven, CT, USA. 18 Yale Cancer Center, Yale University School of Medicine, New Haven, CT, USA. 19 Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, CA, USA. amnewman@stanford.edu. 20 Department of Biomedical Data Science, Stanford University, Stanford, CA, USA. amnewman@stanford.edu. # Contributed equally.

A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti-PD-1 Agent Pembrolizumab

Adusumilli PS, et al.
Cancer Discovery
January 2022
Authors and Affiliates
Prasad S Adusumilli 1,2,3, Marjorie G Zauderer 2,4, Isabelle Rivière 3,5, Stephen B Solomon 6, Valerie W Rusch 7, Roisin E O'Cearbhaill 2,8, Amy Zhu 7, Waseem Cheema 7, Navin K Chintala 7, Elizabeth Halton 2, John Pineda 2, Rocio Perez-Johnston 6, Kay See Tan 2,9, Bobby Daly 4, Jose A Araujo Filho 6, Daniel Ngai 7, Erin McGee 7, Alain Vincent 7, Claudia Diamonte 2, Jennifer L Sauter 10, Shanu Modi 2,11, Devanjan Sikder 5, Brigitte Senechal 5, Xiuyan Wang 5, William D Travis 10, Mithat Gönen 9, Charles M Rudin 4, Renier J Brentjens 2,3, David R Jones 7, Michel Sadelain 3; 1 Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York. adusumip@mskcc.org. 2 Cellular Therapeutics Center, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. 3 Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, New York. 4 Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. 5 Michael G. Harris Cell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer Center, New York, New York. 6 Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York. 7 Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York. 8 Gynecologic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. 9 Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York. 10 Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York. 11 Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.

DJ‐1 depletion prevents immunoaging in T‐cell compartments

Zeng N, et al.
January 2022
Authors and Affiliates
Ni Zeng 1,2, Christophe M Capelle 1,2, Alexandre Baron 1, Takumi Kobayashi 1, Severine Cire 1, Vera Tslaf 1,2,3, Cathy Leonard 1, Djalil Coowar 4, Haruhiko Koseki 5,6, Astrid M Westendorf 7, Jan Buer 7, Dirk Brenner 1,4, Rejko Krüger 3,4,8, Rudi Balling 4, Markus Ollert 1,9, Feng Q Hefeng 1,7; 1 Department of Infection and Immunity, Luxembourg Institute of Health (LIH), Esch-sur-Alzette, Luxembourg. 2 Faculty of Science, Technology and Medicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg. 3 Transversal Translational Medicine, Luxembourg Institute of Health (LIH), Strassen, Luxembourg. 4 Luxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, Belvaux, Luxembourg. 5 Laboratory for Developmental Genetics, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan. 6 AMED-CREST, Japanese Agency for Medical Research and Development, Yokohama, Japan. 7 Institute of Medical Microbiology, University Hospital Essen, University Duisburg-Essen, Essen, Germany. 8 Centre Hospitalier de Luxembourg (CHL), Luxembourg, Luxembourg. 9 Department of Dermatology and Allergy Center, Odense Research Center for Anaphylaxis (ORCA), University of Southern Denmark, Odense, Denmark.
Previous Next